1. Home
  2. Analysis
  3. Epivir
  4. Testosterone-cypionate

Epivir and Testosterone cypionate drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Epivir (lamivudine) and Testosterone cypionate (testosterone cypionate). Common drug interactions include anxiety among males.

The phase IV clinical study analyzes what interactions people have when they take Epivir and Testosterone cypionate. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Epivir?

Epivir has active ingredients of lamivudine. It is often used in hiv infection. eHealthMe is studying from 16,870 Epivir users. Check the latest studies of Epivir.

What is Testosterone cypionate?

Testosterone cypionate has active ingredients of testosterone cypionate. It is often used in testosterone. eHealthMe is studying from 1,926 Testosterone cypionate users. Check the latest studies of Testosterone cypionate.

On Jul, 20, 2026

11 people who take Epivir and Testosterone cypionate together, and have interactions are studied.

Epivir and Testosterone cypionate drug interactions.

What are the common drug interactions of Epivir and Testosterone Cypionate, by gender? *:

female:

n/a

male:

  1. Anxiety
  2. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  3. Asthenia (weakness)
  4. Decreased activity
  5. Decreased interest
  6. Depressed mood
  7. Drug ineffective
  8. Fanconi syndrome acquired (self developed genetic disease of kidney damage due to defective transport system)
  9. Osteopenia (a condition where bone mineral density is lower than normal)
  10. Renal failure (kidney dysfunction)

What are the common drug interactions of Epivir and Testosterone Cypionate, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

  1. Anhedonia (inability to experience pleasure from activities usually found enjoyable)
  2. Anxiety
  3. Bone disorder
  4. Bone loss
  5. Bone pain
  6. Depression
  7. Drug resistance (reduction in effectiveness of a drug)
  8. Gait disturbance
  9. Impaired work ability
  10. Mobility decreased (ability to move is reduced)

50-59:

n/a

60+:

n/a

What are the existing conditions these people have? *

  1. Hiv Infection: 10 people, 90.91%
  2. Pain: 2 people, 18.18%
  3. High Blood Cholesterol: 1 person, 9.09%
  4. Back Pain: 1 person, 9.09%
  5. Bone Pain: 1 person, 9.09%
  6. Depression: 1 person, 9.09%
  7. Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 9.09%
  8. Gastroesophageal Reflux Disease (a condition in which stomach contents leak backward from the stomach into the oesophagus): 1 person, 9.09%
  9. Hepatitis A: 1 person, 9.09%
  10. Hepatitis B: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Epivir and Testosterone cypionate?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Epivir and Testosterone cypionate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Epivir:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Testosterone cypionate:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Epivir and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Testosterone cypionate and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on lamivudine and testosterone cypionate (the active ingredients of Epivir and Testosterone cypionate, respectively), and Epivir and Testosterone cypionate (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.